Related Experiment Video
Updated: Jan 31, 2026
04:23
A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease
Published on: April 28, 2019
7.1K
Dengue drug discovery: Progress, challenges and outlook
1Denka Life Innovation Research, 21 Biopolis Road, 03-21/22, Nucleos, Singapore, 138567, Singapore.
Antiviral Research
|January 1, 2019
Summary
Developing new dengue virus (DENV) antivirals is crucial due to vaccine risks. Recent drug discovery efforts show promise, targeting viral and host proteins for effective dengue treatments.
Area of Science:
- Virology
- Drug Discovery
- Public Health
Background:
- The sole dengue virus (DENV) vaccine, DENGVAXIA, presents risks for unexposed individuals.
- Developing effective antiviral therapies for dengue is a significant public health priority.
Purpose of the Study:
- To review recent advancements in DENV drug discovery from academic and industrial research.
- To outline the characteristics of an ideal DENV antiviral agent.
- To discuss challenges and opportunities in developing dengue drugs.
Main Methods:
- Review of recent progress in DENV drug discovery.
- Identification of new chemical classes targeting viral (NS4B) and host proteins.
- Application of "omics" methodologies for flavivirus inhibitor discovery.
Main Results:
- Promising new chemical classes targeting viral and host proteins have been identified.
- Advanced methodologies like "omics" can accelerate the discovery of specific inhibitors.
- Challenges and opportunities in lead identification and clinical development are discussed.
Conclusions:
- Despite challenges, DENV drug discovery offers promising opportunities.
- Collaborative partnerships and open-access resources are vital to accelerate DENV drug development for patient benefit.
Related Concept Videos
01:26Drug Discovery: Overview
11.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.5K
02:07Tumor Progression
7.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.4K
03:03mTOR Signaling and Cancer Progression
4.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.8K
01:25Pharmacokinetics: Drug–Drug Interactions
440
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
440
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
158
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
158
01:26FDA Approved Drugs: Changes to Approved Drugs
268
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
268